Facebook Twitter Instagram
    • Home
    • About Journal
      • Aim and Scope
      • Editorial Board
      • Indexing Info
      • Contact Us
    • Browse Issues
      • Articles in Press
      • Current Issue
      • Past Issues
    • For Authors
      • Instructions to Authors
      • Article Processing Charges
      • Submit your article
      • Downloads
    Facebook Twitter Instagram
    Pharmacognosy Communications
    • Home
    • About Journal
      • Aim and Scope
      • Editorial Board
      • Indexing Info
      • Contact Us
    • Browse Issues
      • Articles in Press
      • Current Issue
      • Past Issues
    • For Authors
      • Instructions to Authors
      • Article Processing Charges
      • Submit your article
      • Downloads
    Pharmacognosy Communications
    retyeyutreu
    Original Article

    High-Throughput Screening by In silico Molecular Docking of Eryngium Foetidum (Linn.) Bioactives for Cylcooxygenase-2 Inhibition

    wadmin2By wadmin2August 6, 2016Updated:August 11, 2021No Comments2 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    Share
    Facebook Twitter LinkedIn WhatsApp Pinterest Email

    Pavan Rangahanumaiah1, Ravishankar Vittal Rai2, Asma Saqhib3, Lydia Jothi3, Marula Siddha Swamy1, Chandrakant Shivappa Karigar3 and Shailasree Sekhar1*
    1Institution of Excellence, Vijnana Bhavana, University of Mysore, Mysuru – 570006, Karnataka, INDIA.
    2Department of Studies in Microbiology, University of Mysore, Mysuru – 570 006, Karnataka, INDIA.
    3Department of Biochemistry, Bangalore University, Bengaluru– 560 056, Karnataka, INDIA.

    Pharmacognosy Communications,2016,6,4,232-237.
    DOI:10.5530/pc.2016.4.6
    Published: August 2016
    Type: Original Article

    ABSTRACT

    Several studies are in progress worldwide to find natural healing agents with better safety profiles. Our current study aimed to screen and evaluate Eryngium foetidum Linn. bioactives reported for therapeutic drug discovery by In silico docking. Ligands /bioactives were prepared by following the appropriate procedures and finally In silico molecular docking to cyclooxygenase (COX)-2 was performed and analyzed by FleX X. Of the docked bioactives, caryophyllene oxide in particular, showed high binding affinity of -7.00 kcal/mol against 1PXX corroborating in vitro COX-2 inhibition and providing a theoretical contribution in understanding the ligand-protein interactions. The docked pose resembled the orientation similar to that observed with diclofenac ligand (inhibitor of COX-2). The ligand was docked deeply within the binding pocket region forming interactions with ALA527GLY526LEU352SER530TYR348TRP387VAL349VAL523 and Ser353. Our docking result was found to have three hydrogen bonding sites with SER530TYR348 and TYR385, indicating COX-2 inhibition with the highest fitness score of 50.64. Furthermore, all the bioactives were subjected to iLOG predictor of the Swiss ADMET website software generating In silico ADME properties and testing their capacity to exhibit drug likeliness. The data supports caryophyllene oxide to be a potent anti-inflammatory compound worthy of further clinical trials.

    Key words: Eryngium foetidum, Swiss Dock, cyclooxygenase-2 inhibitor, iLOG predictor of the Swiss ADMET, Caryophyllene oxide.

    Download PDF
    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    About Journal
    About Journal

    Pharmacognosy Communications [Phcog Commn.] is a quarterly journal published by Phcog.Net. It is a peer reviewed journal aiming to publish high quality original research articles, methods, techniques and evaluation reports, critical reviews, short communications, commentaries and editorials of all aspects of medicinal plant research. The journal is aimed at a broad readership, publishing articles on all aspects of pharmacognosy, and related fields. The journal aims to increase understanding of pharmacognosy as well as to direct and foster further research through the dissemination of scientific information by the publication of manuscripts. The submission of original contributions in all areas of pharmacognosy are welcome.
    Indexed and Abstracted in : Chemical Abstracts, Excerpta Medica / EMBASE, Google Scholar, CABI Full Text, Ulrich’s International Periodical Directory, ProQuest, Journalseek & Genamics, PhcogBase, EBSCOHost, Academic Search Complete, Open J-Gate, SciACCESS.
    Rapid publication: Average time from submission to first decision is 30 days and from acceptance to In Press online publication is 45 days.
    Open Access Journal: Phcog Commn. is an open access journal, which allows authors to fund their article to be open access from publication.

    © 2025 Pharmacognosy Communications. Maintained by Manuscript TechnoMedia LLP.

    Type above and press Enter to search. Press Esc to cancel.

    Scroll Up